Numerion Labs

numerionlabs.ai →

-39%

est. 2Y upside i

HealthcareSeries C

Artificial intelligence for drug discovery.

Rank

#1630

Sector

Drug Discovery

Est. Liquidity

~3Y

Data Quality

Data: Low

Numerion Labs presents a moderate upside opportunity for a job seeker, driven by its strong competitive moat with patented AI technology and significant partnerships in a rapidly growing AI drug discovery market.

Last updated: March 10, 2026

Bull (30%)+150%

Successful clinical trials for a key drug candidate, combined with expanded partnerships with major pharmaceutical companies, could drive revenue significantly above projections, justifying a $3.75B+ valuation (2.5x current assumed valuation) as the company becomes a leader in AI-driven small molecule discovery.

Base (38%)+40%

Numerion Labs continues to secure new discovery partnerships and advance its pre-clinical pipeline, achieving steady revenue growth in line with the expanding AI drug discovery market. This would support a valuation of approximately $2.1B (1.4x current assumed valuation) at a liquidity event, reflecting its strong technology but also ongoing competitive pressures.

Bear (32%)—

Increased competition from well-funded rivals or significant setbacks in clinical development for key drug candidates could slow growth and lead to a down round or a lower acquisition price, resulting in a valuation of $750M (0.5x current assumed valuation) and a substantial loss for common shareholders due to liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Investors hold $226M in liquidation preferences, meaning common stock holders would only see returns after this amount is paid out in an exit.

Dilution Risk

moderate

As a Series C company, it's likely to have at least one more significant funding round before an exit, which will cause further dilution.

Secondary Liquidity

none

There is no public information indicating active secondary markets or tender offers for Numerion Labs' equity.

Questions to Ask at the Interview

Strategic questions based on Numerion Labs's data — designed to show you've done your homework.

  • 1

    “Given the 'medium' incumbent threat and the significant investments by large pharma like Eli Lilly and Novo Nordisk into AI drug discovery, how does Numerion Labs plan to maintain its competitive edge and market share in the long term?”

  • 2

    “Numerion Labs is currently in the pre-clinical trials stage. What are the key milestones and timelines for advancing drug candidates through clinical trials, and how does the company manage the associated risks and capital requirements?”

  • 3

    “With total funding of $226M and a Series C round in February 2025, what is the company's current valuation, and what are the anticipated next funding steps or liquidity events for employees holding equity?”

Community

Valuation Sentiment

Our model estimates -39% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.